Amyris Overview

  • Founded
  • 2003
Founded
  • Status
  • Public
  • Employees
  • 595
Employees
  • Stock Symbol
  • AMRS
Stock Symbol
  • Investments
  • 11
  • Share Price
  • $14.36
  • (As of Monday Closing)

Amyris General Information

Description

Amyris Inc is an industrial biotechnology company. It is engaged in the engineering, manufacturing, and sales of products in a variety of consumer and industrial markets, including cosmetics, flavors and fragrances, solvents and cleaners, polymers, lubricants, healthcare products, and fuels. The business operations are spread across the world with the majority of the revenues generated in the United States. The company generates revenue from the sale of renewable products, licenses of and royalties from intellectual property, and grants, and collaborative research and development services.

Contact Information

Website
www.amyris.com
Formerly Known As
Amyris Biotechnologies
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Stock Exchange
NAS
Primary Office
  • 5885 Hollis Street
  • Suite 100
  • Emeryville, CA 94608
  • United States
+1 (510) 000-0000

Amyris Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Amyris Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$14.36 $14.56 $1.88 - $23.42 $4.15B 289M 4.77M -$1.88

Amyris Financials Summary

In Thousands,
USD
TTM 31-Dec-2020 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 1,638,887 1,638,887 552,997 398,688
Revenue 173,137 173,137 152,557 63,604
EBITDA (263,773) (263,773) (166,295) (182,611)
Net Income (331,039) (331,039) (242,767) (230,235)
Total Assets 222,814 222,814 160,966 127,925
Total Debt 282,187 282,187 289,065 209,892
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Amyris Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Amyris‘s full profile, request access.

Request a free trial

Amyris Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Amyris‘s full profile, request access.

Request a free trial

Amyris Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Amyris Inc is an industrial biotechnology company. It is engaged in the engineering, manufacturing, and sales of product
Biotechnology
Emeryville, CA
595 As of 2020
00.000
000000000 00.000

00000000

enderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupi
0000000000000
Bagsvaerd, Denmark
0000 As of 0000
00000000

0000000

velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident,
0000000000000
Redwood City, CA
000 As of 0000
00000
000000 - 000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Amyris Competitors (7)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Novozymes Corporation Bagsvaerd, Denmark 0000 00000000
0000000 Formerly VC-backed Redwood City, CA 000 00000 000000 - 000 00000
0000000 Corporation Roslin, United Kingdom 0 0000000000
0000000 Venture Capital-Backed Gainesville, FL 0 000.00 0000000000 0 000.00
00000000000 000000 Venture Capital-Backed Vancouver, Canada 00 000.00 0000000000 000.00
You’re viewing 5 of 7 competitors. Get the full list »

Amyris Executive Team (32)

Name Title Board Seat Contact Info
John Melo President, Chief Executive Officer & Board Member
Hermanus Kieftenbeld Chief Financial Officer, Finance & Chief Administrative Officer, Administration
Eduardo Alvarez Chief Operating Officer
Francisco Costa Chief Creative Officer
Christine Ofori Chief People Officer
You’re viewing 5 of 32 executive team members. Get the full list »

Amyris Board Members (21)

Name Representing Role Since
Carole Piwnica JD Self Board Member 000 0000
Frank Kung Ph.D Self Board Member 000 0000
Geoffrey Duyk Ph.D Self Board Member 000 0000
James McCann Self Board Member 000 0000
John Melo Amyris President, Chief Executive Officer & Board Member 000 0000
You’re viewing 5 of 21 board members. Get the full list »

Amyris Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Amyris Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Amyris‘s full profile, request access.

Request a free trial

Amyris Investments & Acquisitions (11)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 0000 000000 14-Apr-2021 000000000000000000 00000 Application Software 0000 0000
0000 000000 000000 16-Mar-2021 00000 0000000 Food Products
00000 000000 01-Mar-2021 000000000000000000 Personal Products 0000 0000
000000000 26-Jan-2021 000000000000000000 Other Pharmaceuticals and Biotechnology
Terasana Beauty Company 22-Jan-2021 Merger/Acquisition Personal Products 0000 0000
You’re viewing 5 of 11 investments and acquisitions. Get the full list »

Amyris Subsidiaries (1)

Company Name Industry Location Founded
000000000 Other Pharmaceuticals and Biotechnology Columbus, OH 0000
To view Amyris’s complete subsidiaries history, request access »